S. 476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

Before you vote › Federal bills

S. 476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

116th Congress · introduced 2019-02-13 · Health · Latest: Read twice and referred to the Committee on Finance.

federal

Save to my notebook What does this mean? Print

Official title

Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

Plain summary

Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 This bill establishes a series of requirements relating to drug rebates and discounts under Medicare and Medicare Advantage (MA). Specifically, for each pharmacy benefits manager (PBM) that contracts with a prescription drug plan (PDP) under Medicare or MA, or with a qualified health benefits plan offered through a health insurance exchange, HHS must publish on its website (1) the amount and type of rebates and discounts negotiated by the PBM and the extent to which these rebates and discounts are passed on to the plan sponsor, and (2) the difference between the amount paid by the plan sponsor to the PBM and the amount paid by the PBM to pharmacies. As a condition of participation as a contractor under Medicare or MA, a PBM must pass on to a PDP sponsor a minimum percentage, as established by HHS, of the amount of rebates and discounts negotiated by the PBM that are attributable to patient utilization under the plan. The bill also modifies requirements regarding Medicare enrollees' access to negotiated drug prices. Current law requires a PDP sponsor to provide enrollees in Medicare or MA with access to negotiated drug prices that account for rebates and discounts. The bill requires that, with respect to a covered drug, a negotiated price (or, if necessary, an approximate negotiated price) be provided at the point of sale.

Congressional Research Service summary (Introduced in Senate), quoted unchanged (nonpartisan). Read the source.

What a vote does

PSI Sci description of the legislative step (not an opinion).

The strongest published arguments

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Sen. Wyden, Ron [D-OR] · 5 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

Christopher A. Coons (D-DE), Edward J. Markey (D-MA)

Sponsor's campaign money: Sen. Wyden, Ron [D-OR] reported raising $1.9 million (2025–2026). Details. Shown for context only; it does not mean any donor supported this bill.

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Sources

• Congressional Research Service summary (Introduced in Senate)
• Congress.gov
• Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-116s476.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/116/s>

Record fed-us-cong116-s476 · catalog fed-us-congress-bills-cong116 · updated 2026-11-15 by psicol fed-bills-cong116